ArticleCancer immunology, immunotherapy : CII2023

Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.

Kenji Morimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.